Olaparib
Who holds supplier records for Olaparib? 20 organisations hold a current record for Olaparib: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: India (11), China (4), Taiwan (1) and Italy (1); not recorded for 3.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Olaparib: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/olaparib
Reading the evidence
- 20 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- Most recorded organisations are in India
11 of the 17 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.
- 13 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Olaparib expires 25 Oct 2041. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (20)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Olaparib. Country is the organisation's recorded country, not necessarily the manufacturing site.
- BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITEDIndiaActive DMF 40467, 43716 · latest filing Mar 2026
- Hetero Labs LimitedIndia Company GMP cert on recordActive DMF 35831, 43374 · latest filing Apr 2026
- HUADONG MEDICINE (XI'AN) BODYGUARD PHARMACEUTICAL CO LTDActive DMF 40462, 42596 · latest filing Nov 2025
- MSN Laboratories Private LimitedIndia Company GMP cert on recordActive DMF 43952, 34698 · latest filing Mar 2026
- SCINOPHARM TAIWAN LTDTaiwanActive DMF 32629, 42340 · latest filing Sept 2025
- Alembic Pharmaceuticals LimitedIndia Company GMP cert on recordActive DMF 32505 · latest filing Mar 2018
- ALIVUS LIFE SCIENCES LTDIndia Company GMP cert on recordActive DMF 38957 · latest filing Sept 2023
- ALP PHARM BEIJING CO LTDActive DMF 31219 · latest filing Dec 2016
- BDR LIFESCIENCES PRIVATE LIMITEDIndia Company GMP cert on recordActive DMF 42527 · latest filing Sept 2025
- Biocon LimitedIndiaActive DMF 41344 · latest filing Mar 2025
- CAMBREX PROFARMACO MILANO SRLItaly Company GMP cert on recordActive DMF 39524 · latest filing Feb 2024
- CDYMAX (INDIA) PHARMA PRIVATE LIMITEDIndia Company GMP cert on recordActive DMF 42143 · latest filing Jun 2025
- Cipla LimitedIndia Company GMP cert on recordActive DMF 37240 · latest filing Aug 2022
- Deva Holding AsCompany GMP cert on recordActive DMF 43529 · latest filing Feb 2026
- Dr. Reddy's Laboratories Ltd.India Company GMP cert on recordActive DMF 35742 · latest filing Mar 2021
- Intas Pharmaceuticals Ltd.India Company GMP cert on recordActive DMF 42359 · latest filing Sept 2025
- Shandong Anhong Pharmaceutical Co., Ltd.China Company GMP cert on recordActive DMF 38395 · latest filing Jun 2023
- Sichuan Kelun Pharmaceutical Co., Ltd.ChinaActive DMF 40679 · latest filing Oct 2024
- Wisdom Pharmaceutical Co., LtdChinaActive DMF 38136 · latest filing Mar 2023
- Zhejiang Ausun Pharmaceutical Co., Ltd.China Company GMP cert on recordActive DMF 41845 · latest filing Apr 2025
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (2 listed products contain Olaparib). The latest listed patent expires 25 Oct 2041. The latest listed exclusivity runs to 8 May 2027. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Olaparib is a potent oral PARP inhibitor with anti-tumor activity, specifically designed to exploit the DNA-repair pathway deficiencies in cancer cells. It is primarily used for the treatment of ovarian, breast, and certain other types of cancer linked to BRCA mutations.
Chemical identity
- IUPAC name
- 4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one
- Canonical SMILES
- C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F
- InChIKey
- FDLYAMZZIXQODN-UHFFFAOYSA-N
- Synonyms
- Lynparza API, az-2281, az2281, azd-2281, azd2281, keylynk-010 component olaparib, ku-0059436, ku-59436, lynparza, nsc-747856
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Poly(ADP-Ribose) Polymerase Inhibitor
- Mechanism of action
- Poly(ADP-Ribose) Polymerase Inhibitors
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Olaparib?
20 organisations hold an active US FDA Type II Drug Master File or a CEP for Olaparib: BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (India), Hetero Labs Limited (India), HUADONG MEDICINE (XI'AN) BODYGUARD PHARMACEUTICAL CO LTD, MSN Laboratories Private Limited (India), SCINOPHARM TAIWAN LTD (Taiwan), Alembic Pharmaceuticals Limited (India), ALIVUS LIFE SCIENCES LTD (India) and ALP PHARM BEIJING CO LTD, and 12 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Olaparib Drug Master Files are active?
BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (DMF 40467, 43716), Hetero Labs Limited (DMF 35831, 43374), HUADONG MEDICINE (XI'AN) BODYGUARD PHARMACEUTICAL CO LTD (DMF 40462, 42596), MSN Laboratories Private Limited (DMF 43952, 34698), SCINOPHARM TAIWAN LTD (DMF 32629, 42340), Alembic Pharmaceuticals Limited (DMF 32505), ALIVUS LIFE SCIENCES LTD (DMF 38957) and ALP PHARM BEIJING CO LTD (DMF 31219) and 12 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
Does the FDA Orange Book list patents for products containing Olaparib?
Yes. The latest patent listed for an approved US product containing Olaparib expires 25 Oct 2041, across 2 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Olaparib supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Olaparib?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.